Current status of toxoplasmosis vaccine development

References

• Lautenslager JP. Toxoplasmosis as a significant disease in man and animals with special reference to preventive measures by the farm community. Can. Vet. J.28(5), 261–264 (1987).
   PubMedGoogle Scholar
• Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet363(9425), 1965–1976 (2004).
   PubMed Web of Science ®Google Scholar
• Dubey JP, Jones JL. Toxoplasma gondii infection in humans and animals in the United States. Int. J. Parasitol.38(11), 1257–1278 (2008).
   PubMed Web of Science ®Google Scholar
• Buxton D, Innes EA. A commercial vaccine for ovine toxoplasmosis. Parasitology110, 11–16 (1995).
   PubMed Web of Science ®Google Scholar
• Buxton D. Protozoan infections (Toxoplasma gondii, Neospora caninum and Sarcocystis spp.) in sheep and goats: recent advances. Vet. Res.29(3–4), 289–310 (1998).
   PubMed Web of Science ®Google Scholar
• Vercruysse J, Knox DP, Schetters TP, Willadsen P. Veterinary parasitic vaccines: pitfalls and future directions. Trends Parasitol.20(10), 488–492 (2004).
   PubMedGoogle Scholar
• Innes EA, Vermeulen AN. Vaccination as a control strategy against the coccidial parasites Eimeria, Toxoplasma and Neospora. Parasitology133, 145–168 (2006).
   PubMed Web of Science ®Google Scholar
• Araujo FG. Immunization against Toxoplasma gondii. Parasitol. Today10(9), 358–360 (1994).
   PubMedGoogle Scholar
• O’Connell E, Wilkins MF, Te Punga WA. Toxoplasmosis in sheep. II. The ability of a live vaccine to prevent lamb losses after an intravenous challenge with Toxoplasma gondii. NZ Vet. J.36(1), 1–4 (1988).
   PubMed Web of Science ®Google Scholar
• Wilkins MF, O’Connell E, Te Punga WA. Toxoplasmosis in sheep III. Further evaluation of the ability of a live Toxoplasma gondii vaccine to prevent lamb losses and reduce congenital infection following experimental oral challenge. NZ Vet. J.36(2), 86–89 (1988).
   PubMed Web of Science ®Google Scholar
• Buxton D, Thomson KM, Maley S, Wright S, Bos HJ. Experimental challenge of sheep 18 months after vaccination with a live (S48) Toxoplasma gondii vaccine. Vet. Rec.133(13), 310–312 (1993).
   PubMed Web of Science ®Google Scholar
• Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int. J. Parasitol.30(12–13), 1217–1258 (2000).
   PubMed Web of Science ®Google Scholar
• Gazzinelli RT, Amichay D, Sharton-Kersten T, Grunwald E, Farber JM, Sher A. Role of macrophage derived cytokines in the induction and regulation of cell mediated immunity to Toxoplasma gondii. Curr. Top. Microbiol. Immunol.219, 127–140 (1996).
   PubMedGoogle Scholar
• Sher A, Reis e Sousa C. Ignition of the type 1 response to intracellular infection by dendric cell derived IL-12. Eur. Cytokine Netw.9(3), 65–68 (1998).
   PubMedGoogle Scholar
• Sibley LD, Adam SL, Fukutomi Y. Tumor necrosis factor-α triggers antitoxoplasmal activity of IFN-γ primed macrophages. J. Immunol.147(7), 2340–2345 (1991).
   PubMedGoogle Scholar
• Sher A, Oswald IP, Hieny S, Gazzinelli RT. Toxoplasma gondii induces a T independent IFN-γ response in natural killer cells that requires both adherant accessory cells and tumor necrosis factor-α. J. Immunol.150(9), 3982–3989 (1993).
   PubMed Web of Science ®Google Scholar
• Langermans JAM, Van Der Hulst MEB, Nibbering PH, Hiemstra OPS, Fransen L, Van Furth R. INF-γ induced L-arginine dependent toxoplasmastatic activity in murine peritoneal macrophages is mediated by endogenous tumor necrosis factor-α. J. Immunol.148(2), 568–574 (1992).
   PubMedGoogle Scholar
• Sher A, Collazzo C, Scanga C, Jankovic D, Yap G, Aliberti J. Induction and regulation of IL-12-dependent host resistance to Toxoplasma gondii. Immunol Res.27(2–3), 521–528 (2003).
   PubMedGoogle Scholar
• Luft BJ, Remington JS. Toxoplasmatic encephalitis in AIDS. Clin. Infect. Dis.15, 211–222 (1992).
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Orellana MA, Schreiber RD, Remington JS. Interferon-γ: the major mediator of resistance against Toxoplasma gondii. Science240(4851), 516–518 (1988).
   PubMed Web of Science ®Google Scholar
• Sayles PC, Gibson GW, Johnson LL. B cells are essential for vaccination-induced resistance to virulent Toxoplasma gondii. Infect. Immun.68(3), 1026–1033 (2000).
   PubMed Web of Science ®Google Scholar
• Johnson LL, Sayles PC. Deficient humoral responses underlie susceptibility to Toxoplasma gondii in CD4-deficient mice. Infect. Immun.70(1), 185–191 (2002).
   PubMed Web of Science ®Google Scholar
• Buxton D. Toxoplasmosis: the first commercial vaccine. Parasitol. Today9(9), 335–337 (1993).
   PubMedGoogle Scholar
• Frenkel JK, Pfefferkorn ER, Smith DD, Fishback JL. Prospective vaccine prepared from a new mutant of Toxoplasma gondii for use in cats. Am. J. Vet. Res.52(5), 759–763 (1991).
   PubMed Web of Science ®Google Scholar
• Lindsay DS. Blagburn BL, Dubey JP. Safety and results of challenge of weaned pigs given a temperature sensitive mutant of Toxoplasma gondii. J. Parasitol.79(1), 71–76 (1993).
   PubMedGoogle Scholar
• Gatkowska J, Gąsior A, Kur J, Długońska H. Toxoplasma gondii: chimeric Dr fimbriae as a recombinant vaccine against toxoplasmosis. Exp. Parasitol.118(2), 266–270 (2008).
   PubMedGoogle Scholar
• Couper KN, Nielsen HV, Petersen E, Roberts F, Roberts CW, Alexander J. DNA vaccination with the immunodominant tachyzoite surface antigen (SAG-1) protects against adult acquired Toxoplasma gondii infection but does not prevent maternofoetal transmission. Vaccine21(21–22), 2813–2820 (2003).
   PubMedGoogle Scholar
• Dimier-Poisson I, Aline F, Bout D, Mévélec MN. Induction of protective immunity against toxoplasmosis in mice by immunization with Toxoplasma gondii RNA. Vaccine24(10), 1705–1709 (2006).
   PubMed Web of Science ®Google Scholar
• Cong H, Gu QM, Jiang Y et al. Oral immunization with a live recombinant attenuated Salmonella typhimurium protects mice against Toxoplasma gondii. Parasite Immunol.27(1–2), 29–35 (2005).
   PubMed Web of Science ®Google Scholar
• Siachoque H, Guzman F, Burgos J, Patarroyo ME, Gomez-Marin JE. Toxoplasma gondii: immunogenicity and protection by P30 peptides in a murine model. Exp. Parasitol.114(1), 62–65 (2006).
   PubMed Web of Science ®Google Scholar
• Fox BA, Bzik DJ. De novo pyrimidine biosynthesis is required for virulence of Toxoplasma gondii. Nature415, 925–929 (2002).
   Google Scholar
• Spencer JA, Smith BF, Guarino AJ, Blagburn BL, Baker HJ. The use of CpG as an adjuvant to Toxoplasma gondii vaccination. Parasitol. Res.92(4), 313–316 (2004).
   PubMedGoogle Scholar
• Denkers EY, Gazzinelli RT. Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clin. Microbiol. Rev.11(4), 569–588 (1998).
   PubMed Web of Science ®Google Scholar
• Boothroyd JC, Hehl A, Knoll LJ, Manger ID. The surface of Toxoplasma: more or less. Int. J. Parasitol.28(1), 3–9 (1997).
   Google Scholar
• Jung C, Lee CY, Grigg ME. The SRS superfamily of Toxoplasma surface proteins. Int. J. Parasitol.34(3), 285–296 (2004).
   PubMedGoogle Scholar
• Lekutis C, Ferguson DJ, Grigg ME, Camps M, Boothroyd JC. Surface antigens of Toxoplasma gondii: variations on a theme. Int. J. Parasitol.31(12), 1285–1292 (2001).
   PubMedGoogle Scholar
• Grimwood J, Smith JE. Toxoplasma gondii: the role of parasite surface and secreted proteins in host cell invasion. Int. J. Parasitol.26(2), 169–173 (1996).
   PubMed Web of Science ®Google Scholar
• Mineo JR, Kasper LH. Attachment of Toxoplasma gondii to host cells involves major surface protein, SAG-1 (P30). Exp. Parasitol.79(1), 11–20 (1994).
   PubMed Web of Science ®Google Scholar
• Debard N, Buzoni-Gatel D, Bout D. Intranasal immunization with SAG1 protein of Toxoplasma gondii in association with cholera toxin dramatically reduces development of cerebral cysts after oral infection. Infect. Immun.64(6), 2158–2166 (1996).
   PubMed Web of Science ®Google Scholar
• Bulow R, Boothroyd JC. Protection of mice from fatal Toxoplasma gondii infection by immunization with p30 antigen in liposomes. J. Immunol.147(10), 3496–3500 (1991).
   PubMed Web of Science ®Google Scholar
• Petersen E, Nielsen HV, Christiansen L, Spenter J. Immunization with E. coli produced recombinant T. gondii SAG1 with alum as adjuvant protect mice against lethal infection with Toxoplasma gondii. Vaccine16(13), 1283–1289 (1998).
   PubMed Web of Science ®Google Scholar
• Letscher-Bru V, Villard O, Risse B, Zauke M, Klein JP, Kien TT. Protective effect of vaccination with a combination of recombinant surface antigen 1 and IL 12 against toxoplasmosis in mice. Infect. Immun.66(9), 4503–4506 (1998).
   PubMed Web of Science ®Google Scholar
• Biemans R, Grégoire D, Haumont M et al. The conformation of purified Toxoplasma gondii SAG1 antigen, secreted from engineered Pichia pastoris, is adequate for serorecognition and cell proliferation. J. Biotech.66(2–3), 137–146 (1998).
   PubMedGoogle Scholar
• Haumont M, Delhaye L, Garcia L et al. Protective immunity against congenital toxoplasmosis with recombinant SAG1 protein in a guinea pig model. Infect. Immun.68(9), 4948–4953 (2000).
   PubMedGoogle Scholar
• Chen XG, Fung MC, Ma X, Peng HJ, Shen SM, Liu GZ. Baculovirus expression of the major surface antigen of Toxoplasma gondii mice injected with the recombinant and the immune response of P30. Southeast Asian J. Trop. Med. Public Health30(1), 42–46 (1999).
   PubMedGoogle Scholar
• Darcy F, Maes P, Gras-Masse H. Protection of mice and nude rats against toxoplasmosis by a multiple antigenic peptide construction derived from Toxoplasma gondii P30 antigen. J. Immunol.149(11), 3636–3641 (1992).
   PubMed Web of Science ®Google Scholar
• Godard I, Estaquier J, Zenner L et al. Antigenicity and immunogenicity of P30-derived peptides in experimental models of toxoplasmosis. Mol. Immunol.31(17), 1353–1363 (1994).
   PubMedGoogle Scholar
• Velge-Roussel F, Moretto M, Buzoni-Gatel D. Differences in immunological response to a T. gondii protein (SAG1) derived peptide between two strains of mice: eVect on protection in T. gondii infection. Mol. Immunol.34(15), 1045–1053 (1997).
   PubMedGoogle Scholar
• Caetano BC, Bruña-Romero O, Fux B, Mendes EA, Penido ML, Gazzinelli RT. Vaccination with replication-deficient recombinant adenoviruses encoding the main surface antigens of Toxoplasma gondii induces immune response and protection against infection in mice. Hum Gene Ther.17(4), 415–426 (2006).
   PubMedGoogle Scholar
• Lau YL, Fong MY. Toxoplasma gondii: serological characterization and immunogenicity of recombinant surface antigen 2 (SAG2) expressed in the yeast Pichia pastoris. Exp Parasitol.119(3), 373–378 (2008).
   PubMed Web of Science ®Google Scholar
• Nielsen HV, Lauemoller SL, Christiansen L, Buus S, Fomsgaard A, Petersen E. Complete protection against lethal Toxoplasma gondii infection in mice immunized with a plasmid encoding the SAG1 gene. Infect. Immun.67(12), 6358–6363 (1999).
   PubMedGoogle Scholar
• Angus CW, Klivington-Evans D, Dubey JP, Kovacs JA. Immunization with a DNA plasmid encoding the SAG1 (P30) protein of Toxoplasma gondii is immunogenic and protective in rodents. J. Infec. Dis.181(1), 317–324 (2000).
   PubMed Web of Science ®Google Scholar
• Letscher-Bru V, Pfaff AW, Abou-Bacar A et al. Vaccination with Toxoplasma gondii SAG-1 protein is protective against congenital toxoplasmosis in BALB/c mice but not in CBA/J mice. Infect. Immun.71(11), 6615–6619 (2003).
   PubMed Web of Science ®Google Scholar
• Kim JJ, Ayyavoo V, Bagarazzi ML et al.In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J. Immunol.158(2), 816–826 (1997).
   PubMed Web of Science ®Google Scholar
• Chow YH, Chiang BL, Lee YL et al. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by co-delivery of various cytokine genes. J. Immunol.160(3), 1320–1329 (1998).
   PubMed Web of Science ®Google Scholar
• Sin JI, Kim JJ, Arnold RL et al. IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+T cell-mediated protective immunity against herpes simplex virus-2 challenge. J. Immunol.162(5), 2912–2921 (1999).
   PubMed Web of Science ®Google Scholar
• Fachado A, Rodriguez A, Angel SO et al. Protective effect of a naked DNA vaccine cocktail against lethal toxoplasmosis in mice. Vaccine21(13–14), 1327–1335 (2003).
   PubMedGoogle Scholar
• Mévélec MN, Bout D, Desolme B et al. Evaluation of protective effect of DNA vaccination with genes encoding antigens GRA4 and SAG1 associated with GM-CSF plasmid, against acute, chronical and congenital toxoplasmosis in mice. Vaccine23(36), 4489–4499 (2005).
   PubMed Web of Science ®Google Scholar
• Beghetto E, Nielsen HV, Del Porto P et al. A combination of antigenic regions of Toxoplasma gondii microneme proteins induces protective immunity against oral infection with parasite cysts. J. Infect. Dis.191(4), 637–645 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang J, He S, Jiang H et al. Evaluation of the immune response induced by multiantigenic DNA vaccine encoding SAG1 and ROP2 of Toxoplasma gondii and the adjuvant properties of murine IL-12 plasmid in BALB/c mice. Parasitol. Res.101(2), 331–338 (2007).
   PubMed Web of Science ®Google Scholar
• Cui YL, He SY, Xue MF, Zhang J, Wang HX, Yao Y. Protective effect of a multiantigenic DNA vaccine against Toxoplasma gondii with co-delivery of IL-12 in mice. Parasite Immunol.30(5), 309–313 (2008).
   PubMed Web of Science ®Google Scholar
• Xue M, He S, Zhang J, Cui Y, Yao Y, Wang H. Comparison of cholera toxin A2/B and murine IL-12 as adjuvants of Toxoplasma multi-antigenic SAG1–ROP2 DNA vaccine. Exp. Parasitol.119(3), 352–357 (2008).
   PubMed Web of Science ®Google Scholar
• Xue M, He S, Cui Y, Yao Y, Wang H. Evaluation of the immune response elicited by multi-antigenic DNA vaccine expressing SAG1, ROP2 and GRA2 against Toxoplasma gondii. Parasitol. Int.57(4), 424–429 (2008).
   PubMedGoogle Scholar
• Jongert E, Verhelst D, Abady M, Petersen E, Gargano N. Protective Th1 immune responses against chronic toxoplasmosis induced by a protein–protein vaccine combination but not by its DNA–protein counterpart. Vaccine26(41), 5289–5295 (2008).
   PubMed Web of Science ®Google Scholar
• Qu D, Wang S, Cai W, Du A. Protective effect of a DNA vaccine delivered in attenuated Salmonella typhimurium against Toxoplasma gondii infection in mice. Vaccine26(35), 4541–4548 (2008).
   PubMed Web of Science ®Google Scholar
• Carruthers VB, Sibley LD. Sequential protein secretion from three distinct organelles of Toxoplasma gondii accompanies invasion of human fibroblasts. Eur. J. Cell. Biol.73, 114–123 (1997).
   PubMed Web of Science ®Google Scholar
• Garcia JL, Gennari SM, Navarro IT et al. Partial protection against tissue cysts formation in pigs vaccinated with crude rhoptry proteins of Toxoplasma gondiiVet. Parasitol.129(3–4), 209–217 (2005).
   PubMed Web of Science ®Google Scholar
• Garcia JL, Navarro IT, Biazzono L et al. Protective activity against oocyst shedding in cats vaccinated with crude rhoptry proteins of the Toxoplasma gondii by the intranasal route. Vet. Parasitol.145(3–4), 197–206 (2007).
   PubMed Web of Science ®Google Scholar
• Vercammen M, Scorza T, Huygen K et al. DNA vaccination with genes encoding Toxoplasma gondii antigens GRA1, GRA7, and ROP2 induces partially protective immunity against lethal challenge in mice. Infect. Immun.68(1), 38–45 (2000).
   PubMed Web of Science ®Google Scholar
• Leyva R, Hérion P, Saavedra R. Genetic immunization with plasmid DNA coding for the ROP2 protein of Toxoplasma gondii. Parasitol. Res.87(1), 70–79 (2001).
   PubMed Web of Science ®Google Scholar
• Wei QK, Li J, Fu TX et al. Studies on the immunoprotection of ROP2 nuclei acid vaccine in Toxoplasma gondii infection. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi24(5), 337–341 (2006).
   PubMedGoogle Scholar
• Roque-ReséNdiz JL, Rosales R, Herion P. MVA ROP2 vaccinia virus recombinant as a vaccine candidate for toxoplasmosis. Parasitology128(4), 397–405 (2004).
   PubMed Web of Science ®Google Scholar
• Mishima M, Xuan X, Yokoyama N et al. Recombinant feline herpesvirus type 1 expressing Toxoplasma gondii ROP2 antigen inducible protective immunity in cats. Parasitol. Res.88(2), 144–149 (2002).
   PubMed Web of Science ®Google Scholar
• Wang H, Liu Q, Liu K et al. Immune response induced by recombinant Mycobacterium bovis BCG expressing ROP2 gene of Toxoplasma gondii. Parasitol. Int.56(4), 263–268 (2007).
   PubMedGoogle Scholar
• Martin V, Supanitsky A, Echeverria PC et al. Recombinant GRA4 or ROP2 protein combined with alum or the gra4 gene provides partial protection in chronic murine models of toxoplasmosis. Clin. Diagn. Lab. Immunol.11(4), 704–710 (2004).
   PubMedGoogle Scholar
• Echeverria PC, de Miguel N, Costas M, Angel SO. Potent antigen-specific immunity to Toxoplasma gondii in adjuvant-free vaccination system using Rop2–Leishmania infantum Hsp83 fusion protein. Vaccine24(19), 4102–4110 (2006).
   PubMed Web of Science ®Google Scholar
• Soldati D, Dubremetz JF, Lebrun M. Microneme proteins: structural and functional requirements to promote adhesion and invasion by the apicomplexan parasite Toxoplasma gondii. Int. J. Parasitol.31(12), 1293–1302 (2001).
   PubMedGoogle Scholar
• Tomley FM, Soldati DS. Mix and match modules: structure and function of microneme proteins in apicomplexan parasites. Trends Parasitol.17(2), 81–88 (2001).
   PubMedGoogle Scholar
• Meissner M, Reiss M, Viebig N et al. A family of transmembrane microneme proteins of Toxoplasma gondii contain EGF-like domains and function as escorters. J. Cell Sci.115(3), 563–574 (2002).
   PubMed Web of Science ®Google Scholar
• Reiss M, Viebig N, Brecht S et al. Identification and characterization of an escorter for two secretory adhesins in Toxoplasma gondii. J. Cell Biol.152(3), 563–578 (2001).
   PubMed Web of Science ®Google Scholar
• Lourenço EV, Bernardes ES, Silva NM, Mineo JR, Panunto-Castelo A, Roque-Barreira MC. Immunization with MIC1 and MIC4 induces protective immunity against Toxoplasma gondii. Microbes Infect.8(5), 1244–1251 (2006)
   PubMedGoogle Scholar
• Ismael AB, Sekkai D, Collin C, Bout D, Mevelec MN. The MIC3 gene of Toxoplasma gondii is a novel potent vaccine candidate against toxoplasmosis. Infect. Immun.71(11), 6222–6228 (2003).
   PubMedGoogle Scholar
• Dautu G, Munyaka B, Carmen G et al.Toxoplasma gondii: DNA vaccination with genes encoding antigens MIC2, M2AP, AMA1 and BAG1 and evaluation of their immunogenic potential. Exp. Parasitol.116(3), 273–282 (2007).
   PubMed Web of Science ®Google Scholar
• Capron A, Dessaint JP. Vaccination against parasitic diseases, some alternative concepts for the definition of protective antigens. Ann. Inst. Pasteur Immunol.139(1), 109–117 (1988).
   PubMedGoogle Scholar
• Cesbron MF, Capron A. Excreted-secreted antigens of Toxoplasma gondii: their origin and role in the host parasite interaction. Res. Immunol.144(1), 41–44 (1993).
   PubMedGoogle Scholar
• Cesbron-Delauw MF. Dense granule organelles of Toxoplasma gondii: their role in the host parasite relationship. Parasitol. Today10(8), 293–296 (1994).
   PubMedGoogle Scholar
• Hughes HP, van Knapen F. Characterisation of a secretory antigen from Toxoplasma gondii and its role in circulating antigen production. Int. J. Parasitol.12(5), 433–437 (1982).
   PubMed Web of Science ®Google Scholar
• Asai T, Kim TJ, Kobayashi M, Kojima S. Detection of nucleoside triphosphate hydrolase as a circulating antigen in sera of mice infected with Toxoplasma gondii. Infect. Immun.55(5), 1332–1335 (1987).
   PubMedGoogle Scholar
• Hassl A, Aspock H. Detection and characterization of circulating antigens in acute experimental infections of mice with four different strains of Toxoplasma gondii. Zentralbl Bakteriol.272(4), 526–534 (1990).
   PubMedGoogle Scholar
• Mercier C, Adjogble KD, Daubener W, Cesbron-Delauw MF. Dense granules: are they key organelles to help understand the parasitophorous vacuole of all apicomplexa parasites? Int. J. Parasitol.35(8), 829–849 (2005).
   PubMed Web of Science ®Google Scholar
• Murray A, Mercier C, Decoster A, Lecordier L, Capron A, Cesbron-Delauw MF. Multiple B-cell epitopes in a recombinant GRA2 secreted antigen of Toxoplasma gondii. Appl. Parasitol.34(4), 235–244 (1993).
   PubMedGoogle Scholar
• Golkar M, Rafati S, Taslimi Y, Taheri T, Doustdari F, Assmar M. High level expression and evaluation of the antigenicity of a recombinant Toxoplasma gondii GRA2 protein. Iranian J. Biotech.2, 170–176 (2004).
   Google Scholar
• Prigione I, Facchetti P, Lecordier L et al. T cell clones raised from chronically infected healthy humans by stimulation with Toxoplasma gondii excretory-secretory antigens cross-react with live tachyzoites: characterization of the fine antigenic specificity of the clones and implications for vaccine development. J. Immunol.164(7), 3741–3748 (2000).
   PubMed Web of Science ®Google Scholar
• Cesbron-Delauw MF, Lecordier L, Mercier C. Role of secretory dense granule organelles in the pathogenesis of toxoplasmosis. Curr. Top. Microbiol. Immunol.219, 59–65 (1996).
   PubMedGoogle Scholar
• Zenner L, Estaquier J, Darcy F, Maes P, Capron A, Cesbron-Delauw MF. Protective immunity in the rat model of congenital toxoplasmosis and the potential of excreted-secreted antigens as vaccine components. Parasite Immunol.21(5), 261–272 (1999).
   PubMed Web of Science ®Google Scholar
• Zhou H, Gu Q, Zhao Q et al. Toxoplasma gondii: expression and characterization of a recombinant protein containing SAG1 and GRA2 in Pichia pastoris. Parasitol. Res.100(4), 829–835 (2007).
   PubMedGoogle Scholar
• Ferrandiz J, Mercier C, Wallon M, Picot S, Cesbron-Delauw MF, Peyron F. Limited value of assays using detection of immunoglobulin G antibodies to the two recombinant dense granule antigens, GRA1 and GRA6 Nt of Toxoplasma gondii, for distinguishing between acute and chronic infections in pregnant women. Clin. Diagn. Lab. Immunol.11(6), 1016–1021 (2004).
   PubMedGoogle Scholar
• Peyron F, Lobry JR, Musset K et al. Serotyping of Toxoplasma gondii in chronically infected pregnant women: predominance of type II in Europe and types I and III in Colombia (South America). Microbes Infect.8 (9–10), 2333–2340 (2006).
   PubMed Web of Science ®Google Scholar
• Gatkowska J, Hiszczynska-Sawicka E, Kur J, Holec L, Dlugonska H. Toxoplasma gondii: an evaluation of diagnostic value of recombinant antigens in a murine model. Exp. Parasitol.114(3), 220–227 (2006).
   PubMedGoogle Scholar
• Golkar M, Shokrgozar MA, Rafati S et al. Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against Toxoplasma chronic infection in mice. Vaccine25(21), 4301–4311 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang G, Huong VT, Battur B et al. A heterologous prime-boost vaccination regime using DNA and a vaccinia virus, both expressing GRA4, induced protective immunity against Toxoplasma gondii infection in mice. Parasitology134(10), 1339–1346 (2007).
   PubMedGoogle Scholar
• Di Cristina M, Del Porto P, Buffolano W et al. The Toxoplasma gondii bradyzoite antigens BAG1 and MAG1 induce early humoral and cell-mediated immune responses upon human infection. Microbes Infect.6(2), 164–171 (2004).
   PubMedGoogle Scholar
• Bohne W, Gross U, Ferguson DJ, Heesemann J. Cloning and characterization of a bradyzoite-specifically expressed gene (hsp30/bag1) of Toxoplasma gondii, related to genes encoding small heat-shock proteins of plants. Mol. Microbiol.16(6), 1221–1230 (1995).
   PubMedGoogle Scholar
• Parmley SF, Weiss LM, Yang S. Cloning of a bradyzoite-speciffic gene of Toxoplasma gondii encoding a cytoplasmic antigen. Mol. Biochem. Parasitol.73 (1–2), 253–257 (1995).
   PubMedGoogle Scholar
• Parmley SF, Yang S, Harth G, Sibley LD, Sucharczuk A, Remington JS. Molecular characterization of a 65-kilodalton Toxoplasma gondii antigen expressed abundantly in the matrix of tissue cysts. Mol. Biochem. Parasitol.66(2), 283–296 (1994).
   PubMedGoogle Scholar
• Mun HS, Aosai F, Yano A. Role of Toxoplasma gondii HSP70 and Toxoplasma gondii HSP30/bag1 in antibody formation and prophylactic immunity in mice experimentally infected with Toxoplasma gondii. Microbiol. Immunol.43(5), 471–479 (1999).
   PubMedGoogle Scholar
• Parmley SF, Slifer T, Araujo F. Protective effects of immunization with a recombinant cyst antigen in mouse models of infection with Toxoplasma gondii tissue cysts. J. Infect. Dis.185(l), 90–95 (2002).
   Google Scholar
• Nielsen HV, Di Cristina M, Beghetto E, Spadoni A, Petersen E, Gargano N. Toxoplasma gondii: DNA vaccination with bradyzoite antigens induces protective immunity in mice against oral infection with parasite cysts. Exp. Parasitol.112, 274–279 (2006).
   PubMedGoogle Scholar
• Lundén A, Lövgren K, Uggla A, Araujo FG. Immune responses and resistance to Toxoplasma gondii in mice immunized with antigens of the parasite incorporated into immunostimulating complexes. Infect. Immun.61(6), 2639–2643 (1993).
   PubMedGoogle Scholar
• Stanley AC, Buxton D, Innes EA, Huntley JF. Intranasal immunisation with Toxoplasma gondii tachyzoite antigen encapsulated into PLG microspheres induces humoral and cell-mediated immunity in sheep. Vaccine22(29–30), 3929–3941 (2004).
   PubMed Web of Science ®Google Scholar
• Costa-Silva TA, Meira CS, Ferreira IM, Hiramoto RM, Pereira-Chioccola VL. Evaluation of immunization with tachyzoite excreted-secreted proteins in a novel susceptible mouse model (A/Sn) for Toxoplasma gondii. Exp. Parasitol.120(3), 227–234 (2008).
   PubMedGoogle Scholar
• Chen G, Chen H, Guo H, Zheng H. Protective effect of DNA-mediated immunization with a combination of SAG1 and IL-2 gene adjuvant against infection of Toxoplasma gondii in mice. Chin. Med. J. (Engl.)115(10), 1448–1452 (2002).
   PubMed Web of Science ®Google Scholar
• Lundén A, Parmley SF, Bengtsson KL, Araujo FG. Use of a recombinant antigen, SAG2, expressed as a glutathione-S-transferase fusion protein to immunize mice against Toxoplasma gondii. Parasitol. Res.83(1), 6–9 (1997).
   PubMedGoogle Scholar
• Yang CD, Chang GN, Chao D. Protective immunity against Toxoplasma gondii in mice induced by a chimeric protein rSAG1/2. Parasitol Res.92(1), 58–64 (2004).
   PubMed Web of Science ®Google Scholar
• Lee YH, Shin DW, Lee JH, Nam HW, Ahn MH. Vaccination against murine toxoplasmosis using recombinant Toxoplasma gondii SAG3 antigen alone or in combination with Quil A. Yonsei Med. J.48(3), 396–404 (2007).
   PubMedGoogle Scholar
• Chen H, Chen G, Zheng H, Guo H. Induction of immune responses in mice by vaccination with liposome-entrapped DNA complexes encoding Toxoplasma gondiiSAG1 and ROP1 genes. Chin. Med. J. (Engl.)116(10), 1561–1566 (2003).
   PubMedGoogle Scholar
• Jongert E, Melkebeek V, De Craeye S, Dewit J, Verhelst D, Cox E. An enhanced GRA1–GRA7 cocktail DNA vaccine primes anti-Toxoplasma immune responses in pigs. Vaccine26(8), 1025–1031 (2008).
   PubMed Web of Science ®Google Scholar
• Jongert E, de Craeye S, Dewit J, Huygen K. GRA7 provides protective immunity in cocktail DNA vaccines against Toxoplasma gondii. Parasite Immunol.29(9), 445–453 (2007).
   PubMed Web of Science ®Google Scholar
• Igarashi M, Kano F, Tamekuni K. Toxoplasma gondii: cloning, sequencing, expression, and antigenic characterization of ROP2, GRA5 and GRA7. Genet. Mol. Res.7(2), 305–313 (2008).
   PubMedGoogle Scholar
• Guo H, Chen G, Lu F, Chen H, Zheng H. Immunity induced by DNA vaccine of plasmid encoding the rhoptry protein 1 gene combined with the genetic adjuvant of pcIFN-γ against Toxoplasma gondii in mice. Chin. Med. J. (Engl.)114(3), 317–320 (2001).
   PubMedGoogle Scholar
• Chen G, Guo H, Lu F, Zheng H. Construction of a recombinant plasmid harbouring the rhoptry protein 1 gene of Toxoplasma gondii and preliminary observations on DNA immunity. Chin. Med. J. (Engl.)114(8), 837–840 (2001).
   PubMedGoogle Scholar
• Scorza T, D’Souza S, Laloup M et al. A GRA1 DNA vaccine primes cytolytic CD8+ T cells to control acute Toxoplasma gondii infection. Infect. Immun.71(1), 309–316 (2003).
   PubMedGoogle Scholar
• Bivas-Benita M, Laloup M, Versteyhe S et al. Generation of Toxoplasma gondii GRA1 protein and DNA vaccine loaded chitosan particles: preparation, characterization, and preliminary in vivo studies. Int. J. Pharm.266(1–2), 17–27 (2003).
   PubMed Web of Science ®Google Scholar
• Desolme B, Mévélec MN, Buzoni-Gatel D, Bout D. Induction of protective immunity against toxoplasmosis in mice by DNA immunization with a plasmid encoding Toxoplasma gondii GRA4 gene. Vaccine18(23), 2512–2521 (2000).
   PubMed Web of Science ®Google Scholar